对于接受局部区域治疗的肝细胞癌患者，通过肝脏衰弱指数评估的身体功能随时间保持稳定。
Physical Function as Assessed by the Liver Frailty Index Remains Stable Over Time in Patients With Hepatocellular Carcinoma Treated With Locoregional Therapies.
作者信息
Hu Madeleine D, Chiou Sy Han, Delk Molly, Fenton Cynthia, Lai Jennifer C, Li Michael
机构信息
Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Department of Statistics and Data Science, Southern Methodist University, Dallas, Texas, USA.
出版信息
Clin Transl Gastroenterol. 2025 May 6;16(6):e00854. doi: 10.14309/ctg.0000000000000854. eCollection 2025 Jun 1.
INTRODUCTION
It is unknown how frailty evolves over time in patients with hepatocellular carcinoma who are treated with locoregional therapies (LRTs).
METHODS
We conducted a retrospective study of LRT-treated hepatocellular carcinoma patients with Liver Frailty Index (LFI) assessments. Linear mixed-effects modeling was used to assess the impact of time (modeled linearly per month) and other variables on LFI.
RESULTS
Of 201 patients enrolled, median baseline LFI was 3.54. LFI did not change significantly over time from study entry ( P = 0.93).
DISCUSSION
In our study, LFI remained stable over time after LRT, suggesting that LRT is generally well tolerated.
引言
对于接受局部区域治疗（LRT）的肝细胞癌患者，衰弱如何随时间演变尚不清楚。
方法
我们对接受LRT治疗且进行了肝脏衰弱指数（LFI）评估的肝细胞癌患者进行了一项回顾性研究。使用线性混合效应模型来评估时间（每月线性建模）和其他变量对LFI的影响。
结果
在纳入的201例患者中，基线LFI中位数为3.54。从研究入组开始，LFI随时间未发生显著变化（P = 0.93）。
讨论
在我们的研究中，LRT后LFI随时间保持稳定，这表明LRT总体耐受性良好。
Zotero 插件